A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus BSC in Asian Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy
Phase of Trial: Phase III
Latest Information Update: 11 Feb 2016
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms CONCUR
- Sponsors Bayer
- 05 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jan 2016 Results of plasma protein biomarker analysis will be presented at the 2016 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology, according to a Bayer media release.
- 14 Sep 2015 Results of biomarker analysis will be presented at the 2015 European Cancer Congress, according to a Bayer media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History